Literature DB >> 15096457

Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice.

Tsuyoshi Hattori1, Hiroaki Shimokawa, Midoriko Higashi, Junko Hiroki, Yasushi Mukai, Hiroyuki Tsutsui, Kozo Kaibuchi, Akira Takeshita.   

Abstract

BACKGROUND: Rho-kinase has been implicated as an important regulator of inflammatory responses mediated by cytokines and chemokines. Because proinflammatory cytokines play a critical role in left ventricular (LV) remodeling after myocardial infarction (MI), we examined whether long-term blockade of Rho-kinase suppresses LV remodeling in a mouse model of MI in vivo. METHODS AND
RESULTS: Mice underwent ligation of the left coronary artery and were treated with a Rho-kinase inhibitor, fasudil (100 mg x kg(-1) x d(-1) in tap water), for 4 weeks, starting 1 day after the surgery. At 4 weeks, LV infarct size was histologically comparable between the 2 groups. LV cavity dilatation and dysfunction evaluated by echocardiography were significantly suppressed in the fasudil group (P<0.05, n=15 to 28). The beneficial effects of fasudil were accompanied by suppression of cardiomyocyte hypertrophy and interstitial fibrosis (both P<0.01, n=6). The expression of inflammatory cytokines, including transforming growth factor (TGF)-beta2, TGF-beta3, and macrophage migration inhibitory factor, was upregulated in the noninfarcted LV in the control group and was significantly suppressed in the fasudil group (both P<0.05, n=10 to 11). Rho-kinase activity as evaluated by the extent of phosphorylation of the ERM family, a substrate of Rho-kinase, was significantly increased in the noninfarcted LV in the control group and was significantly suppressed in the fasudil group (P<0.05, n=5).
CONCLUSIONS: These results indicate that Rho-kinase is substantially involved in the pathogenesis of LV remodeling after MI associated with upregulation of proinflammatory cytokines, suggesting a therapeutic importance of the molecule for the prevention of post-MI heart failure.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15096457     DOI: 10.1161/01.CIR.0000127939.16111.58

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  74 in total

1.  Investigation of the association between Rho/Rho-kinase gene polymorphisms and systemic sclerosis.

Authors:  Yavuz Pehlivan; Servet Yolbas; Gozde Yıldırım Cetin; Fatma Alibaz-Oner; Yonca Cagatay; Neslihan Yilmaz; Serdar Oztuzcu; Salim Donmez; Metin Ozgen; Suleyman Serdar Koca; Omer Nuri Pamuk; Mehmet Sayarlıoglu; Bunyamin Kisacik; Haner Direskeneli; Abdullah Tuncay Demiryurek; Ahmet Mesut Onat
Journal:  Rheumatol Int       Date:  2015-11-28       Impact factor: 2.631

2.  Mechanism of fibrotic cardiomyopathy in mice expressing truncated Rho-associated coiled-coil protein kinase 1.

Authors:  Xiangsheng Yang; Qi Li; Xi Lin; Yanlin Ma; Xiaojing Yue; Zhenyin Tao; Fen Wang; Wallace L Mckeehan; Lei Wei; Robert J Schwartz; Jiang Chang
Journal:  FASEB J       Date:  2012-01-25       Impact factor: 5.191

Review 3.  Rho/Rho-associated coiled-coil forming kinase pathway as therapeutic targets for statins in atherosclerosis.

Authors:  Naoki Sawada; James K Liao
Journal:  Antioxid Redox Signal       Date:  2013-09-24       Impact factor: 8.401

Review 4.  Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil.

Authors:  Jianjian Shi; Lei Wei
Journal:  J Cardiovasc Pharmacol       Date:  2013-10       Impact factor: 3.105

Review 5.  Spectrum of pleiotropic effects of statins in heart failure.

Authors:  Nitin Mathur; Kumudha Ramasubbu; Douglas L Mann
Journal:  Heart Fail Clin       Date:  2008-04       Impact factor: 3.179

Review 6.  Current Management and Future Directions of Heart Failure With Preserved Ejection Fraction: a Contemporary Review.

Authors:  Chayakrit Krittanawong; Marrick L Kukin
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-03-20

7.  Prevention of RhoA activation and cofilin-mediated actin polymerization mediates the antihypertrophic effect of adenosine receptor agonists in angiotensin II- and endothelin-1-treated cardiomyocytes.

Authors:  Asad Zeidan; Xiaohong Tracey Gan; Ashley Thomas; Morris Karmazyn
Journal:  Mol Cell Biochem       Date:  2013-10-06       Impact factor: 3.396

8.  Focal adhesion kinase as a RhoA-activable signaling scaffold mediating Akt activation and cardiomyocyte protection.

Authors:  Dominic P Del Re; Shigeki Miyamoto; Joan Heller Brown
Journal:  J Biol Chem       Date:  2008-10-14       Impact factor: 5.157

9.  Mechanisms of favorable effects of Rho kinase inhibition on myocardial remodeling and systolic function after experimental myocardial infarction in the rat.

Authors:  Claudia Mera; Iván Godoy; Renato Ramírez; Jackeline Moya; María Paz Ocaranza; Jorge E Jalil
Journal:  Ther Adv Cardiovasc Dis       Date:  2015-10-21

10.  The role of rho kinase in sex-dependent vascular dysfunction in type 1 diabetes.

Authors:  Daniel W Nuno; Kathryn G Lamping
Journal:  Exp Diabetes Res       Date:  2010-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.